Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Turoctocog Alfa Pegol

Recombinant protein · Protein replacement · developed by Novo Nordisk

N/A Most advanced trial
NVO Developer
2 Registered trials

What is Turoctocog Alfa Pegol?

Turoctocog alfa pegol (Esperoct) is a commercially available factor VIII product used in haemophilia A.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Esperoct
Drug type
Recombinant protein
Mechanism
Protein replacement
Therapy area
Hematology
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A
UNII
9Y9727LS4D

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05621746 N/A Haemophilia A Completed NVO
NCT04682145 N/A Haemophilia A Enrolling by invitation NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Haemophilia A

More from Novo Nordisk

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Turoctocog Alfa Pegol

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.